IL33 and airway hyperresponsiveness: Because, we could not observe an increase in mast cell density in the lungs following treatment in any of the experimental groups in our model, we hypothesized that the exacerbated airway hyperresponsiveness by IL-33 in OVA exposed mice could be explained by an enhancement of mast cell mediator release as opposed to an increase in mast cell numbers.